Purpose: To evaluate the role of preparedbasic fibroblast growth factor (bFGF) eyedrops in corneal epithelial healing of transgenic mice after excimer laser photoablation. Materials and Methods: In our prospective case series, 60 eyes of 30 mice had uneventful bilateral excimer laser photoablation. In each mouse, 1 eye received the standard topical postoperative therapy with tobramicin, diclofenac and dexamethasone eyedrops, plusbFGF eyedrops 5 μg/10 μl PBS 3 times a day for 1 week, or until corneal reepithelialization was complete. The fellow eye served as the control and received the standard postoperative therapy plus placebo. The mice were monitored daily, commencing the day after surgery and for 7 days, in order to evaluate the corneal reepithelialization rate by using a video slitlamp camera with a cobalt blue light. The mean diameter of the corneal wounds was measured. Videotaped images were recorded and analyzed by computer planimetry. Results: All the eyes treated withbFGF eyedrops healed completely before day 5 after surgery, with a mean reepithelialization time of 90 ± 12 h (standard deviation); the mean reepithelialization time was 124 ± 10 h in those eyes receiving placebo. There were no statistically significant differences between the 2 groups in corneal haze presentation during the follow-up, perhaps because the time period was too brief (7 days). However, corneal clarity on slitlamp biomicroscopy was greater in the study group than in the control group. No side effects or toxic effects were documented. Conclusions: These data suggest that the bFGF significantly accelerates epithelial healing after excimer photoablation. A further clinical study should be performed to prove the results obtained in this study as well as the long-term efficacy of bFGF to prevent corneal haze.

Keywords:
Basic fibroblast growth factor, Corneal wound healing, Excimer laser photoablation, Transgenic mice, Refractive surgery
1.
Paysse EA, Hamill MB, Koch DD, et al: Epithelial healing and ocular discomfort after photorefractive keratectomy in children. J Cataract Refract Surg 2003;29:478–481.
2.
Kuo IC: Corneal wound healing. Curr Opin Ophthalmol 2004;15:311–315.
3.
Patel GM, Chuang AZ, Kiang E, et al: Epithelial healing rates with topical ciprofloxacin, ofloxacin and ofloxacin with artificial tears after photorefractive keratectomy. J Cataract Refract Surg 2000;26:690–694.
4.
Hersh PS, Stulting RD, Steinert RF, et al: Results of phase III excimer laser photorefractive keratectomy for myopia. The Summit PRK Study Group. Ophthalmology 1997;104:1535–1553.
5.
Kasetsuwan N, Wu FM, Hsieh F, et al: Effect of topical ascorbic acid on free radical tissue damage and inflammatory cell influx in the cornea after excimer laser corneal surgery. Arch Ophthalmol 1999;117:649–652.
6.
Kourenkov VV, Mytiagina ON, Kasparov AA, Pavluk AG: Stimulating re-epithelialization after photo-refractive keratectomy. J Refract Surg 1999;15:S234–S237.
7.
Baiocchi S, Frezzotti P, Sforzi C, Caporossi A: Terapia farmacologica nella cheratectomia fotorefrattiva (PRK); in: Chirurgia rifrattiva: principi e tecniche. Rapp Soc Oftalmol Ital. Canelli, Fabiano, 2000.
8.
Esquenazi S, He J, Bazan NG, Bazan HE: Comparison of corneal wound-healing response in photorefractive keratectomy and laser-assisted subepithelial keratectomy. J Cataract Refract Surg 2005;31:1632–1639.
9.
Armstrong D, Santangelo G, Connole E: The distribution of peroxide regulating enzymes in the canine eye. Curr Eye Res 1981;1:225–242.
10.
Hayashi S, Ishimoto S, Wu GS, et al: Oxygen free radical damage in the cornea after excimer laser therapy. Br J Ophthalmol 1997;81:141–144.
11.
Shimmura S, Masumizu T, Nakai Y, et al: Excimer laser-induced hydroxyl radical formation and keratocyte death in vitro. Invest Ophthalmol Vis Sci 1999;40:1245–1249.
12.
Bilgihan A, Bilgihan K, Yis Ö, et al: The effect of excimer laser keratectomy on corneal glutathione-related enzymes in rabbits. Free Radic Res 2003;37:399–403.
13.
Bilgihan K, Bilgihan A, Adiguzel U, et al: Keratocyte apoptosis and corneal antioxidant enzyme activities after refractive corneal surgery. Eye 2002;16:63–68.
14.
Yis Ö, Bilgihan A, Bilgihan K, et al: The effect of excimer laser keratectomy on corneal glutathione peroxidase activities and aqueous humor selenium levels in rabbits. Graefes Arch Clin Exp Ophthalmol 2002;240:499–502.
15.
Bilgihan A, Bilgihan K, Yis Ö, et al: Effects of topical vitamin E on corneal superoxide dismutase, glutathione peroxidase activities and polymorphonuclear leucocyte infiltration after photorefractive keratectomy. Acta Ophthalmol Scand 2003;81:177–180.
16.
Brancato R, Schiavone N, Siano S, et al: Prevention of corneal keratocyte apoptosis after argon fluoride excimer laser irradiation with the free radical scavenger ubiquinone Q10. Eur J Ophthalmol 2000;10:32–38.
17.
Bilgihan K, Ozdek S, Ozogul C, et al: Topical vitamin E and hydrocortisone acetate treatment after photorefractive keratectomy. Eye 2000;14:231–237.
18.
Gospodarowicz D, Neufeld G, Schweigerer L: Fibroblast growth factor: structural and biological properties. J Cell Physiol Suppl 1987;5:15–26.
19.
McFarlane S, McNeil L, Holt C: FGF signaling and target recognition in the developing Xenopus visual system. Neuron 1995;15:1017–1028.
20.
Unsickler K, Groethe C, Otto D, Westerman R: Basic fibroblast growth factor in neurons and its putative functions. Ann NY Acad Sci 1991;68:300–305.
21.
Abraham JA, Mergia A, Whang L, et al: Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986;233:545–548.
22.
Guillonneau X, Regnier-Ricard F, Dupuis C, Courtois Y, Mascarelli F: FGF2-stimulated release of endogenous FGF-1 is associated with reduced apoptosis in retinal pigmented epithelial cells. Exp Cell Res 1997;233:198–206.
23.
Zhu X, Komiya H, Chirino A, Faham S, Fox GM, Arakawa T, Hsu BT, Rees DC: Three-dimensional structure of acidic and basic fibroblast growth factors. Science 1991;251:90–94.
24.
Seddon A, Decker M, Müller T, Armellino D, Kovedsi I, Glutzman Y, Böhlen P: Structure/activity relationships in basic FGF. Ann NY Acad Sci 1991;68:98–108.
25.
Moscatelli D: High and low affinity binding sites for bFGF on cultured cells: absence of a role for low affinity binding in the simulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol 1987;131:123–130.
26.
Assouline M, Morton K, Hutchinson C, Fayein N, Jeanny JC, Pouliquen Y, Courtois Y: In vivo binding of topically applied human bFGF on rabbit corneal epithelial wound. Growth Factors 1989;1:251–261.
27.
Johnson DE, et al: Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol 1990;10:4728–4736.
28.
Partanen J, et al: Diverse receptors of fibroblast growth factors. ProgGrowth Factor Res 1992;4:69–83.
29.
Lindner V, Reidy MA: Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739–3743.
30.
Lindner V, et al: Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991;68:106–113.
31.
Mayahara H, et al: In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. Growth Factors 1993;9:73–80.
32.
Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM: Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor. Nature 1990;347:83–86.
33.
Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM: Basic fibroblast growth factor and local injury protect photoreceptors from light damage in the rat. J Neurosci 1992;12:3554–3567.
34.
Lin N, Fan W, Sheedlo HJ, Turner JE: Basic fibroblast growth factor treatment delays age-related photoreceptor degeneration in Fischer 344 rats. Exp Eye Res 1997;64:239–248.
35.
Karsan A, Yee E, Poirier GG, Zhou P, Craig R, Harlan JM: Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am J Pathol 1997;151:1775–1784.
36.
Klenkler B, Sheardown H: Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp Eye Res 2004;79:677–688.
37.
Eckenstein FP, Shipley GD, Nishi R: Acidic and basic fibroblast growth factors in the nervous system: distribution and differential alteration of levels after injury of central versus peripheral nerve. J Neurosci 1991;11:412–419.
38.
Finklestein SP, Apostolides PJ, Caday CG, et al: Increased basic fibroblast growth factor (bFGF) immunoreactivity at the site of focal brain wounds. Brain Res 1988;460:253–259.
39.
Frautschy SA, Walicke PA, Baird A: Localization of basic fibroblast growth factor and its mRNA after CNS injury. Brain Res 1991;553:291–299.
40.
Gomez-Pinilla F, Cotman CW: Transient lesion-induced increase of basic fibroblast growth factor and its receptor in layer VIb (subplate cells) of the adult rat cerebral cortex. Neuroscience 1992;49:771–780.
41.
Kostyk SK, D’Amore PA, Herman IM, Wagner JA: Optic nerve injury alters basic fibroblast growth factor localization in the retina and optic tract. J Neurosci 1994;14:1441–1449.
42.
Logan A, Frautschy SA, Baird A: Basic fibroblast growth factor and central nervous system injury. Ann NY Acad Sci 1991;638:474–476.
43.
Logan A, Frautschy SA, Gonzalez AM, Baird A: A time course for the focal elevation of synthesis of basic fibroblast growth factor and one of its high-affinity receptors (flg) following a localized cortical brain injury. J Neurosci 1992;12:3828–3837.
44.
Vlodavsky I, et al: Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis. J Cell Biochem 1991;45:167–176.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.